Equity grant: IOVANCE (NASDAQ: IOVA) awards 117,500 RSUs to Chief Regulatory Officer

Rhea-AI Filing Summary

Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 117,500 restricted stock units (RSUs) on common stock. Each RSU represents a right to receive one share if vesting conditions are met. The award vests over three years, with one-third vesting on the first anniversary of grant and the remaining two-thirds vesting in eight equal quarterly installments over the following two years, so long as he remains employed with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Puri Raj K.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	117,500	$0.00	--

Holdings After Transaction: Restricted Stock Units — 117,500 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puri Raj K.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		117,500		(2)	(2)	Common stock	117,500	$0.00	117,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Raj K. Puri	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Raj K. Puri?

IOVANCE BIOTHERAPEUTICS reported a grant of 117,500 restricted stock units to Chief Regulatory Officer Raj K. Puri. These RSUs are a form of equity compensation tied to future vesting rather than an open-market share purchase or sale.

How many IOVANCE BIOTHERAPEUTICS (IOVA) RSUs were granted in this Form 4 filing?

The filing shows a grant of 117,500 restricted stock units linked to IOVANCE BIOTHERAPEUTICS common stock. After this grant, the reporting person holds 117,500 RSUs, reflecting a new equity award rather than a series of market transactions in existing shares.

How do the IOVANCE BIOTHERAPEUTICS (IOVA) RSUs granted to Raj K. Puri vest?

The RSUs vest over three years if Raj K. Puri remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the next two years, starting the quarter after that first anniversary.

What does each IOVANCE BIOTHERAPEUTICS (IOVA) restricted stock unit represent?

Each restricted stock unit represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. Shares are only delivered when vesting conditions are satisfied over time, aligning executive compensation with continued service and the company’s long-term performance.

Was the IOVANCE BIOTHERAPEUTICS (IOVA) RSU grant to Raj K. Puri an open-market transaction?

No, the RSU grant is classified as a grant or award acquisition rather than an open-market trade. It reflects compensation in equity units at a stated price of $0.00 per unit, contingent on future vesting and continued employment with the company.

What position does Raj K. Puri hold at IOVANCE BIOTHERAPEUTICS (IOVA) in this Form 4?

In this Form 4, Raj K. Puri is identified as the Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS. The reported transaction documents his receipt of 117,500 restricted stock units as part of his compensation package, subject to multi-year vesting conditions.